

## BAB VI

### DAFTAR PUSTAKA

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424. doi:10.3322/caac.21492
2. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol.* 2012;61(6):1079-1092. doi:10.1016/j.eururo.2012.02.054
3. Bray F, Piñeros M. Cancer patterns, trends and projections in latin america and the caribbean: A global context. *Salud Publica Mex.* 2016;58(2):104-117. doi:10.21149/spm.v58i2.7779
4. Wong MCS, Goggins WB, Wang HHX, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. *Eur Urol.* 2016;70(5):862-874. doi:10.1016/j.eururo.2016.05.043
5. Brawley OW. Trends in prostate cancer in the United States. *J Natl Cancer Inst - Monogr.* 2012;(45):152-156. doi:10.1093/jncimonographs/lgs035
6. Diamandis EP, Yousef GM, Luo L, Magklara A, Obiezu C V, Gene TKLK. The New Human Kallikrein Gene Family : Implications in Carcinogenesis. 2000;2760(99):54-60.
7. Chemistry C, Hospital G. Molecular cloning of human prostate specific antigen cDNA. 1987;214(2):317-322.
8. McCormack RT, Rittenhouse HG, D RLSPH. MOLECULAR FORMS OF PROSTATE-SPECIFIC ANTIGEN AND THE HUMAN KALLIKREIN GENE FAMILY A NEW ERA. 1995.
9. Henttu P, Liao S, Vikho P. Androgens Up-Regulate the Human Prostate-Specific Antigen Messenger Ribonucleic Acid (mRNA), but Down-Regulate the Prostatic Acid Phosphatase mRNA in the LNCaP Cell Line. *Endocrinology.* 1992;130:766-772. doi:10.1210/endo.130.2.1370795

10. Etzioni R, Tsodikov AE, Mariotto EA, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. 2008;175-181. doi:10.1007/s10552-007-9083-8
11. World Health Organization. Indonesia Source GLOBOCAN 2018. *Int Agency Res Cancer*. 2019;256:1-2. <http://gco.iarc.fr/>.
12. Indonesian Society of Urologic Oncology (ISUO) meeting. 2011. Unpublished data.
13. Hemminki K. Familial risk and familial survival in prostate cancer. *World J Urol*. 2012;30(2):143-148. doi:10.1007/s00345-011-0801-1
14. Jansson KF, Akre O, Garmo H, et al. Concordance of tumor differentiation among brothers with prostate cancer. *Eur Urol*. 2012;62(4):656-661. doi:10.1016/j.eururo.2012.02.032
15. Randazzo M, Müller A, Carlsson S, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: Results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). *BJU Int*. 2016;117(4):576-583. doi:10.1111/bju.13310
16. Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. *J Natl Cancer Inst*. 2016;108(10):1-7. doi:10.1093/jnci/djw110
17. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. *Int J Cancer*. 1977;20(5):680-688. <http://www.scopus.com/inward/record.url?eid=2-s2.0-0017720307&partnerID=tZOtx3y1>.
18. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. *BMC Cancer*. 2016;16(1):1-13. doi:10.1186/s12885-016-2891-z
19. Key TJ. Nutrition, hormones and prostate cancer risk: Results from the European prospective investigation into cancer and nutrition. *Recent Results Cancer Res*. 2014;202:39-46. doi:10.1007/978-3-642-45195-9\_4

20. Alexander DD, Bassett JK, Weed DL, Barrett EC, Watson H, Harris W. Meta-analysis of long-chain omega-3 polyunsaturated fatty acids (LCω-3PUFA) and prostate cancer. *Nutr Cancer*. 2015;67(4):543-554. doi:10.1080/01635581.2015.1015745
21. Lippi G, Mattiuzzi C. Fried food and prostate cancer risk: Systematic review and meta-analysis. *Int J Food Sci Nutr*. 2015;66(5):587-589. doi:10.3109/09637486.2015.1056111
22. Bylsma LC, Alexander DD. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. *Nutr J*. 2015;14(1). doi:10.1186/s12937-015-0111-3
23. Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk: Results from the Selenium and Vitamin E Cancer Prevention Trial. *Cancer Epidemiol Biomarkers Prev*. 2014;23(8):1494-1504. doi:10.1158/1055-9965.EPI-14-0115
24. Nyame YA, Murphy AB, Bowen DK, et al. Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy. *J Clin Oncol*. 2016;34(12):1345-1349. doi:10.1200/JCO.2015.65.1463
25. Cui Z, Liu D, Liu C, Liu G. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. *Medicine (Baltimore)*. 2017;96(5):e5944. doi:10.1097/MD.00000000000005944
26. Allen NE, Travis RC, Appleby PN, et al. Selenium and prostate cancer: Analysis of individual participant data from fifteen prospective studies. *J Natl Cancer Inst*. 2016;108(11):1-8. doi:10.1093/jnci/djw153
27. Lippman SM, Klein EA, Goodman PJ, et al. Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers. *Jama*. 2009;301(1):39. doi:10.1001/jama.2008.864
28. UICC TNM Classification of Malignant Tumours 8th edition.
29. Gleason D, Gleason DF. Classification of prostatic carcinomas. *Cancer Chemother Rep*. 1966;50(3):125-128. *Cancer Chemother*. 1966;50:125-128. doi:10.1097/01.pas.0000173646.99337.b1

30. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: Data based on the modified Gleason scoring system. *BJU Int.* 2013;111(5):753-760. doi:10.1111/j.1464-410X.2012.11611.x
31. Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017;67(3):245-253. doi:10.3322/caac.21391
32. European Association of Urology 2020 EAU Guidelines.
33. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med.* 2015;373(8):737-746. doi:10.1056/NEJMoa1503747
34. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only. 2007;1117-1120. doi:10.1016/j.urology.2007.07.019
35. Gosselaar C, Roobol MJ, Roemeling S, Schro FH. The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. 2008;54:581-588. doi:10.1016/j.eururo.2008.03.104
36. Bosch JLHR, Bohnen AM, Groeneveld FPMJ. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: The krimpen study. *Eur Urol.* 2004;46(6):753-759. doi:10.1016/j.eururo.2004.07.019
37. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ. Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. *Urology.* 2001;57(6):1087-1092. doi:10.1016/S0090-4295(01)00965-7
38. Roehrborn CG. Accurate Determination of Prostate Size via Digital Rectal Examination and Transrectal Ultrasound. *Response.* 4295(98):19-22.
39. Weissfeld JL, Fagerstrom RM, O'Brien B. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control Clin Trials.* 2000;21(6

- Suppl):390-399. doi:10.1016/s0197-2456(00)00094-5
40. Gilbert J, Arraes RF, Verreschi ITN, V DMJGH. Serum Levels of Prostate-Specific Antigen in Normal Boys Throughout Puberty. 2015;18(5):1185-1187.
  41. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP. Prostate Antigen : A New Potential Marker for Prostatic Cancer. 1981;96:89-96.
  42. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt1):407–413.
  43. Klein LT, Lowe FC. THE EFFECTS OF PROSTATIC MANIPULATION ON PROSTATE- SPECIFIC ANTIGEN LEVELS. 1997;24(2):293-297.
  44. Herschman D, Smith S, Catalona J. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. 4295(97):239-243.
  45. Baillargeon J, Ph D, Pollock BH, et al. The Association of Body Mass Index and Prostate-Specific Antigen in a Population-Based Study. 2005;(January):1092-1095. doi:10.1002/cncr.20856
  46. Ban LL, Hamilton RJ, Partin AW, et al. Obesity-Related Plasma Hemodilution With Prostate Cancer. 2015;298(19):2275-2280.
  47. Partin AW. Campbell-Walsh-Wein Urology.
  48. Hammond GL. Endogenous Steroid Levels in the Human Prostate From Birth to Old Age A Comparison of Normal and Diseased Tissues. 1977.
  49. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the Definition of Castrate Levels of Testosterone. 1995;4295(00):1021-1024.
  50. Takayama K ichi, Misawa A, Inoue S. Significance of microRNAs in androgen signaling and prostate cancer progression. *Cancers (Basel)*. 2017;9(8):1-16. doi:10.3390/cancers9080102
  51. Bjurlin MA, Carter HB, Schellhammer P, et al. Optimization of Initial Prostate Biopsy in Clinical Practice : Sampling , Labeling and Specimen Processing. *JURO*. 2013;189(6):2039-2046. doi:10.1016/j.juro.2013.02.072

52. Xue J, Qin Z, Cai H, Zhang C, Li X. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer : a meta-analysis and trial sequential analysis Studies characteristics. 2017;8(14):23322-23336.
53. Roberts AMJ, Bennett HY, Harris PN, Grummet J, Naber K, Wagenlehner FME. Prostate Biopsy Related Infection: a Systematic Review of Risk Factors, Prevention Strategies and Management Approaches. *Urology*. 2016. doi:10.1016/j.urology.2016.12.011
54. National Comprehensive Cancer Network NCCN Prostate Cancer Early Detection Guidelines. 2019.
55. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU Guidelines on Prostate Cancer . Part 1 : Screening , Diagnosis , and Local Treatment with Curative Intent — Update 2013. *Eur Urol*. 2014;65(1):124-137. doi:10.1016/j.eururo.2013.09.046
56. *Ann M. Berger MD, John L. Shuster Jr., Jamie H. Von Roenn - Principles and Practice of Palliative Care and Supportive Oncology (2013, LWW).*
57. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schro FH. Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. 2012;61:11-25. doi:10.1016/j.eururo.2011.08.026
58. Adolfsson J. Watchful waiting and active surveillance: the current position. 2008;154:10-14. doi:10.1111/j.1464-410X.2008.07585.x
59. Beulens AJW, Poel WMBHG Van Der, Basten ANVJP Van, Wijburg RPMCJ. Linking surgical skills to postoperative outcomes : a Delphi study on the robot-assisted radical prostatectomy. *J Robot Surg*. 2019;0(0):0. doi:10.1007/s11701-018-00916-9
60. Walsh PC, Mostwin JL, Buchanan J, Urological B, Hopkins J, Institutions M. Radical Prostatectomy and Cystoprostatectomy with Preservation of Potency . Results Using a New Nerve- sparing Technique. 1984;(April 1982):694-697.
61. A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of

Continence and Erection in Candidates for Radical Prostatectomy An Update.pdf.

62. Fossati N, Willemse PM, Bergh RCN Van Den, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. 2017. doi:10.1016/j.eururo.2016.12.003
63. Wit EMK, Acar C, Grivas N, et al. Sentinel Node Procedure in Prostate Cancer : A Systematic Review to Assess Diagnostic Accuracy. 2017;71:596-605. doi:10.1016/j.eururo.2016.09.007